MENU
+Compare
ALLO
Stock ticker: NASDAQ
AS OF
Dec 12 closing price
Price
$1.51
Change
-$0.04 (-2.58%)
Capitalization
339.34M

ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases... Show more

Industry: #Biotechnology
ALLO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ALLO with price predictions
Dec 11, 2025

ALLO in upward trend: 10-day moving average crossed above 50-day moving average on November 21, 2025

The 10-day moving average for ALLO crossed bullishly above the 50-day moving average on November 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 17, 2025. You may want to consider a long position or call options on ALLO as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALLO just turned positive on November 12, 2025. Looking at past instances where ALLO's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

ALLO moved above its 50-day moving average on November 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 137 cases where ALLO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ALLO moved out of overbought territory on December 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALLO broke above its upper Bollinger Band on December 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.076) is normal, around the industry mean (28.362). P/E Ratio (0.000) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (336.196).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ALLO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 16.00% to -22 cents per share on March 04

Allogene Therapeutics ALLO Stock Earnings Reports
Q4'25
Est.
$-0.22
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.04
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.04
The last earnings report on November 06 showed earnings per share of -18 cents, beating the estimate of -21 cents. With 2.28M shares outstanding, the current market capitalization sits at 339.34M.
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRLRF1.140.06
+5.56%
GREENLAND RES INC.
RTPPF75.531.42
+1.91%
Rio Tinto plc
LYSDY8.640.03
+0.35%
Lynas Rare Earths Limited
NLTBF6.48N/A
N/A
Nolato AB
MSBB15.72-0.03
-0.22%
Mercer Bancorp, Inc.

ALLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+4.73%
CRSP - ALLO
53%
Loosely correlated
+0.87%
BEAM - ALLO
52%
Loosely correlated
+0.40%
RXRX - ALLO
50%
Loosely correlated
-3.98%
FATE - ALLO
47%
Loosely correlated
+1.83%
MRNA - ALLO
46%
Loosely correlated
+2.07%
More